Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics.

Mark Morris, Eamonn Maher

Research output: Contribution to journalArticle

48 Citations (Scopus)


ABSTRACT : Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VHL), the mutation frequency rates of known tumor suppressor genes in RCC are generally low, but the number of genes found to show frequent inactivation by promoter methylation in RCC continues to grow. Here, we review the genes identified as epigenetically silenced in RCC and their relationship to pathways of tumor development. Increased understanding of RCC epigenetics provides new insights into the molecular pathogenesis of RCC and opportunities for developing novel strategies for the diagnosis, prognosis and management of RCC.
Original languageEnglish
Pages (from-to)59
Number of pages1
JournalGenome medicine
Issue number9
Publication statusPublished - 1 Jan 2010


Dive into the research topics of 'Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics.'. Together they form a unique fingerprint.

Cite this